Latest Breaking News On - Annual congress - Page 1 : comparemela.com

foundry-planet.com - B2B Portal: 7 reasons to come to Metal China 2024

7 reasons to come to Metal China 2024

Investigational Antipsychotic Demonstrates Efficacy Without Blocking Dopamine Receptor

Investigational agent KarXT is a first-in-class muscarinic receptor agonist demonstrating antipsychotic efficacy and safety in short- and long-term clinical trials.

New Post-Hoc Analysis of Pooled Phase 3 Data Shows That Inpefa (Sotagliflozin) Reduced Risk of Heart Failure Events in Patients With Preserved Ejection Fraction

Analysis adds to the body of evidence differentiating INPEFA as a dual oral inhibitor of SGLT2 and SGLT1

Sanofi: ASCO: Sarclisa is first anti-CD38 to significantly improve progression-free survival in combination with VRd for newly diagnosed transplant-ineligible multiple myeloma in phase 3

ASCO: Sarclisa is first anti-CD38 to significantly improve progression-free survival in combination with VRd for newly diagnosed transplant-ineligible multiple myeloma in phase 3 Sarclisa, in combination

Press Release: ASCO: Sarclisa is first anti-CD38 to significantly improve progression-free survival in combination with VRd for newly diagnosed transplant-ineligible multiple myeloma in phase 3